Cyclosporine News and Research

RSS
Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

IP Advocate founder settles long-standing legal battle with UGARF

IP Advocate founder settles long-standing legal battle with UGARF

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009